Thrixen
Unlocking the next generation of simple, affordable & accessible diagnostics
Unlocking the next generation of simple, affordable & accessible diagnostics
Thrixen is a biotech/Medtech startup founded in 2021 and based in Singapore. With the slogan "Unlocking the next generation of simple, affordable & accessible diagnostics," Thrixen is dedicated to revolutionizing diagnostic technology for biomarker detection at the chemistry level. The company's aim is to unlock the next generation of diagnostic and health care monitoring tools that are simple and accessible at the point of care/need. Thrixen's innovative approach positions it at the forefront of the biotechnology industry, offering promising potential for disruptive advancements in healthcare. As of now, there is no publicly disclosed information about Thrixen's last investment or the investors involved. Thrixen's focus on advancing diagnostic technology and simplifying health care monitoring holds significant promise for addressing global health challenges.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $7.00M | 2 | 22Health Ventures, John Ballantyne | 29 Apr 2024 |
No recent news or press coverage available for Thrixen.
We care about your data, and we'd love to use cookies make your experience better.
